Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
People with kidney transplants often develop bone disease. One reason for bone disease may be
overactivity of a gland in the neck called the parathyroid gland. Overactivity of the
parathyroid gland may be caused by lack of Vitamin D in the body. It has recently been
discovered that many patients with kidney transplants have low Vitamin D levels. The
investigators are examining the effects of doxercalciferol on parathyroid hormone levels,
proteinuria and bone turnover markers in people who have had a kidney transplant.
Phase:
Phase 4
Details
Lead Sponsor:
Mariana Markell State University of New York - Downstate Medical Center
Collaborator:
Genzyme, a Sanofi Company
Treatments:
1 alpha-hydroxyergocalciferol Cholecalciferol Ergocalciferols Vitamin D Vitamins